There was an interesting twist in the ongoing Dendreon Corp. (NASDAQ: DNDN) story that developed after 5:00 PM Friday. There was a whole series of FORM 4 filings insider sales filings with the SEC. While it is obvious that most of these were options being exercised and company stock grants, it was hard to not notice how many insiders sold stock. If the insiders sold this many shares, it is very likely that other company employees sold as well. This is probably not such a surprise when you have a company’s stock rise tenfold from the lows and when many employees become instant stock option millionaires. But still, there is the hope that Dendreon will have a blockbuster drug for advanced prostate cancer after (and if) PROVENGE is approved by the FDA at some point in 2010. There are many who believe that Dendreon might even now be a takeover target. Considering that, does it at least make you wonder if employees are taking this much money out of the stock?
Read More
RSS Updates
Email Updates

